Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SGP
Strong SellSpyGlass Pharma, Inc. · Healthcare · United States · $878M · Avg Vol: $2M/d
COMPANY DESCRIPTION
SpyGlass Pharma, Inc. is a clinical-stage ophthalmic pharmaceutical company focused on developing a proprietary sustained-release drug delivery platform for the treatment of glaucoma. Its innovative implantable technology aims to provide long-term, continuous medication delivery, addressing patient adherence challenges and potentially improving therapeutic outcomes. The company is poised to disrupt the glaucoma treatment market with its novel drug-device combination.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -1.17 | -1.62 | -1.25 | — | -1.68 | -2.48 | -2.72 | — |
| Shares | 31.9M | 31.9M | 31.9M | 0.0% | 33.4M | — | — | — |
| Debt | 0 | 3.9M | 1.6M | -59.4% | 1.6M | — | — | — |
| Equity | -33.0M | -60.5M | -98.8M | — | — | — | — | — |
| Op CF | -12.3M | -22.0M | -32.7M | — | -46.6M | — | — | — |
| Inv CF | -20.5M | 22.3M | -11.8M | — | — | — | — | — |
| Fin CF | 39.8M | 0.2M | 124.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SGP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SGP | SpyGlass Pharma, Inc.(you) | $878M | 15 | Strong Sell |
| ARDX | Ardelyx, Inc. | $966M | 16 | Strong Sell |
| PHAT | Phathom Pharmaceuticals, Inc. | $701M | 15 | Strong Sell |
| SVRA | Savara Inc. | $1.1B | 15 | Strong Sell |
| CTMX | CytomX Therapeutics, Inc. | $717M | 12 | Strong Sell |
| ANNX | Annexon, Inc. | $959M | 10 | Strong Sell |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $733M | 12 | Strong Sell |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.2B | 12 | Strong Sell |
| GERN | Geron Corporation | $977M | 21 | Sell |
| ACHV | Achieve Life Sciences, Inc. | $817M | 22 | Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%